New combo therapy tested for Tough-to-Treat lung cancer
NCT ID NCT04958811
Summary
This study is testing whether adding a new drug called tiragolumab to two existing cancer drugs (atezolizumab and bevacizumab) can help control advanced non-squamous lung cancer that has worsened after prior treatment. It will enroll about 29 adults whose cancer has specific genetic markers and has progressed on standard therapies. The main goal is to see if this three-drug combination can shrink tumors and delay cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.